These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22292381)

  • 1. [Application of Markov model in post-marketing pharmacoeconomic evaluation of traditional Chinese medicine].
    Wang X; Su X; Sun W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2844-7. PubMed ID: 22292381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
    Xie YM; Wang X; Wang N; Chang YP
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Process and key points of clinical literature evaluation of post-marketing traditional Chinese medicine].
    Liu H; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2848-50. PubMed ID: 22292382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Discussion on development of four diagnostic information scale for clinical re-evaluation of postmarketing herbs].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Dec; 36(24):3548-50. PubMed ID: 22368876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on method on post-marketing traditonal Chinese medicine safety assessment].
    Kou Q; Zhao S; Feng G; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2771-5. PubMed ID: 22292361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research about re-evaluation of screening of traditonal Chinese medicine symptoms item of post-marketing medicine Xuezhikang].
    He W; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2898-900. PubMed ID: 22292395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
    Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation point of rational drug use of traditional Chinese medicine in market].
    Gao R; Sun M; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2807-10. PubMed ID: 22292371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Technical specification for re-evaluation of post-marketing clinical effectiveness of traditional Chinese medicine (first draft)].
    Zhao Y; Yang YY; Wang YX; Yang HM; Wu SX
    Zhongguo Zhong Yao Za Zhi; 2018 Aug; 43(15):3211-3215. PubMed ID: 30200720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sample size calculation in clinical post-marketing evaluation of traditional Chinese medicine].
    Fu Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2904-6. PubMed ID: 22292397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase 0 clinical trials and post-marketed re-evaluation of clinical safety in injection of traditional Chinese medicine].
    Wei X; Zhang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2874-6. PubMed ID: 22292389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Basic requirements on post-marketing clinical re-evaluation of chinese medicine and phase IV clinical trials].
    Xie Y; Wang Y; Tian F; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2764-7. PubMed ID: 22292359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of regular expression in extracting key information from Chinese medicine literatures about re-evaluation of post-marketing surveillance].
    Wang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2888-90. PubMed ID: 22292393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].
    Jiang J; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2811-2. PubMed ID: 22292372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of quality of pharmacoeconomic studies involved in traditional Chinese medicine in China.
    Si L; Yin M; Wang J; Yang S; Zhang J; Wei L
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1049-1060. PubMed ID: 32777958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic Review and Quality Evaluation of Pharmacoeconomic Studies on Traditional Chinese Medicines.
    Yang N; Zhang H; Deng T; Guo JJ; Hu M
    Front Public Health; 2021; 9():706366. PubMed ID: 34414159
    [No Abstract]   [Full Text] [Related]  

  • 18. [Feasibility analysis of application of future contract in Chinese materia medica transaction].
    Huang L; Yang G; Zhang R; Ma C
    Zhongguo Zhong Yao Za Zhi; 2011 Aug; 36(15):2011-6. PubMed ID: 22066430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of nested case-control study on safe evaluation of post-marketing traditional Chinese medicine injection].
    Xiao Y; Zhao Y; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2796-8. PubMed ID: 22292368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of quality traceability system of traditional Chinese medicine].
    Cai Y; Hu H; Ni JY; Wang YT
    Zhongguo Zhong Yao Za Zhi; 2013 Nov; 38(22):3829-33. PubMed ID: 24558859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.